Health and Healthcare
Long Line of Biotech Secondary Stock Offerings (MNKD, IDIX, ISPH, ARIA, ONTY, NBY, SOMX, ARNA, OXGN)
Published:
Last Updated:
It seems that there is another endless line of biotech and emerging pharmaceutical companies which have raised cash or have filed to raise cash. MannKind Corporation (NASDAQ: MNKD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) have all priced secondary offerings of common stock for close to $175 million total among all three offerings this morning alone. Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) had its pricing yesterday of a secondary offering and Oncothyreon Inc. (Nasdaq: ONTY) announced terms for a direct offering of securities. NovaBay Pharmaceuticals, Inc. (NYSE: NBY) filed this week for a capital raise.
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), and OXiGENE, Inc. (NASDAQ: OXGN) have all filed this week with the SEC for the resale of securities by secondary offering and private placement buyers in recent weeks.
You can read the full story with details on each offering over at BioHealthInvestor.com.
And imagine this… it is only Wednesday.
-The 24/7 Wall St. Team
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
